HSBC Holdings plc vs Roivant Sciences Ltd. Common Shares — how do they compare? HSBC Holdings plc trades at $92.98 (market cap $311.92B), while Roivant Sciences Ltd. Common Shares trades at $35.44 (market cap $24.72B). The key difference: HSBC Holdings plc is far larger — about 12.6× Roivant Sciences Ltd. Common Shares's market cap, and HSBC Holdings plc pays a 4.05% dividend while Roivant Sciences Ltd. Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold HSBC Holdings plc for 36 Days and Roivant Sciences Ltd. Common Shares for 1 Days on average.
| HSBC | ROIV | |
|---|---|---|
Market Cap | $311.92B | $24.72B |
Volume | 3,546,658 | 6,279,442 |
Sector | Financials | Health |
52-Week High | $107.86 | $41.81 |
52-Week Low | $65.67 | $16.04 |
Typical Hold Time | 36 Days | 1 Days |
Enterprise Value | $222.19B | $20.99B |
Dividend Yield | 4.05% | — |
Signals from Pluang's Aura AI — not financial advice
HSBC trades at $92.96, down 0.8% with bearish technical indicators. The bank shows strong profitability with 34.54% net margin and 12.44% ROE, while trading at reasonable valuations (P/E 13.23). Recent earnings show mixed results with Q2 beat but Q1 miss. Analyst sentiment is mixed with 38.1% buy ratings amid strategic expansions in US wealth management and Asian markets.
HSBC presents a balanced opportunity with solid fundamentals offset by near-term technical weakness. Growth initiatives in wealth management and Asian markets provide upside potential, while CFO transition and European restructuring pose execution risks. The stock's valuation remains attractive relative to earnings power.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →